Novel radiation-enhancing agents in malignant gliomas

Keyphrases

• Malignant Glioma 100%
• Glioma Patients 100%
• Enhancing Agents 100%
• Newly Diagnosed Glioblastoma 66%
• Tumor 33%
• Radiation Therapy 33%
• Chemotherapy 33%
• Temozolomide Chemotherapy 33%
• Patient Demographics 33%
• Conventional Therapy 33%
• Clinical Outcomes 33%
• Phase I Study 33%
• Cancer Treatment 33%
• Radiation Chemotherapy 33%
• Resistance Level 33%
• Standards of Practice 33%
• 2-year Survival 33%
• Human Neoplasm 33%
• Nitrosurea 33%
• European Organizations 33%
• Biotherapeutics 33%

Medicine and Dentistry

• Glioblastoma 100%
• Chemotherapy 40%
• Neoplasm 20%
• Temozolomide 20%
• Patient Population 20%
• Cancer Treatment 20%
• Tumor 20%
• Nitrosourea 20%
• Biopharmaceuticals 20%
• Radiation Therapy 20%